Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy

Table 1

(a) Demographic, clinical, and pathological manifestations of patients with CIK cells treatment. (b) Demographic, clinical, and pathological manifestations of patients without CIK cells treatment. (c) Comparison of the Motzer Criteria Factors between two groups.

(a)  

Case	Age/sex	Nidus	Pathologic stage before Nx (TNM)	Location of metastases	Disease state before CIK cell treatment	CIK cycles	Disease state after CIK cell treatment	Disease state by the end of followup	PFS (month)	OS (month)
UPN 1	69/M	Left	T1N0M0	—	CR	4	CR	CR	31	31
UPN 2	43/M	Right	T1N0M0	—	CR	4	CR	CR	42	42
UPN 3	60/M	Left	T1N0M0	—	CR	4	CR	CR	37	37
UPN 4	53/M	Left	T2N0M1	Lung	PD	8	PR	SD	17	28
UPN 5	61/M	Left	T1N0M0	—	CR	4	CR	CR	40	40
UPN 6	57/M	Right	T2N0M1	Lung	PD	8	PR	SD	38	41
UPN 7	79/F	Left	T2N1M0	Retroperitoneal lymph nodes	PD	8	SD	SD	12	26
UPN 8	50/M	Right	T1N0M0	—	CR	5	CR	CR	40	40
UPN 9	63/M	Right	T2N0M0	—	CR	4	CR	CR	32	32
UPN 10	47/M	Left	T1N0M1	Brain (left; temporal lobe)	PD	12	SD	SD	33	33

RCC: renal cell carcinoma; CIK: cytokine-induced killer; TNM: tumornodemetastasis.

(b)  

Case	Age/sex	Nidus	Pathologic stage before Nx (TNM)	Location of metastases at the beginning of followup	Disease state at the beginning of followup	Treatment protocols	Disease state after treatment	Disease state by the end of followup	PFS (month)	OS (month)
UPN 11*	64/M	Right	T1N0M0	—	CR	Partial left nephrectomy	CR	CR	22	36
UPN 12	45/F	Left	T1N0M0	—	CR	—		CR	32	32
UPN 13	41/M	Left	T1N0M1	Lung	PR	Chemotherapy + targeted therapy	SD	PD	7	30
UPN 14	77/M	Right	T1N1M0	Retroperitoneal lymph nodes	SD	IFN-𝛼 + IL-2	PR	SD	11	38
UPN 15	27/M	Left	T1N0M0	—	CR	—		CR	40	40
UPN 16	66/M	Left	T1N0M1	Cervical vertebra	PD	Chemotherapy + radiotherapy	SD	PD	12	35
UPN 17	60/M	Right	T2N0M0	—	CR	Chemotherapy	PR	SD	19	36
UPN 18	45/M	Left	T1N0M0	—	CR	—		CR	29	29
UPN 19	65/F	Left	T2N0M1	Right adrenal gland	PR	Chemotherapy	PR	SD	16	32
UPN 20	46/M	Right	T1N0M0	—	CR	—		CR	28	28

∗UPN 11: the patient got left renal metastasis during the course of followup and got CR again after partial left nephrectomy till the end of followup.

(c)  

Factors	Group 1	Group 2	𝑃
Karnofsky performance status (KPS) (𝑛, %)
80–100	6	7	—
60–80	4	3	—
Corrected calcium (mmol/L)	2.311±0.100	2.308±0.089	0.926
LDH level (U/L)	180.83±24.659	191.56±23.176	0.893
Hemoglobin level (g/L)	114.86±15.416	120±16.269	0.634
Time from diagnosis to systemic radical nephrectomy (<1 year) (𝑛, %)	10 (100%)	10 (100%)	—

Group 1: CIK cells treatment group; group 2: control group.
𝑃>0.05; there are no statistical significant differences between two groups.